March 18, 2014PLoS ONEOpen Access

Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study

Q: What is the clinical evidence from this study?

Study design: Cohort. Population: Venous thromboembolism in cancer and non-cancer subjects (n=25160). Intervention: Pre-cancer platelet count ≥295×10^9/L (>80th percentile) vs. Pre-cancer platelet count <235×10^9/L (<40th percentile). Primary outcome: Symptomatic venous thromboembolism (VTE) in cancer patients (HR 1.98, 95% CI 1.21-3.23).

View Full Paper

Ask AI

Bookmark

Key result

In cancer patients, a pre-cancer platelet count above the 80th percentile (≥295×10^9/L) was associated with a 2-fold higher risk of symptomatic venous thromboembolism (HR 1.98) compared to a platelet count below the 40th percentile.

Why the study?

Does elevated pre-cancer platelet count increase the risk of symptomatic venous thromboembolism in subjects who subsequently develop cancer?

Population

25,160 initially cancer-free subjects who participated in the Tromsø Study in 1994-1995, of whom 2,082 were…

Comparison

Pre-cancer platelet count above the 80th… vs Pre-cancer platelet count below the 40th…

Design

Cohort

Follow-up

up to December 31st, 2009

Authors

HJHilde Jensvoll KBKristine Blix SBSigrid K. Brækkan

Discussion

Member takes

Overview

May flag higher VTE risk in cancer; extends observational links but leaves open validation and trials.

Study Design

Type

Cohort (n=25,160)

Multicenter

Structured PICO

Does elevated pre-cancer platelet count increase the risk of symptomatic venous thromboembolism in subjects who subsequently develop cancer?

Population

25,160 initially cancer-free adults aged over 24 years from the Tromsø Study, followed for up to 15 years to assess the risk of symptomatic venous thromboembolism in those who did and did not develop cancer.

Exposure

Pre-cancer platelet count above the 80th percentile (≥295×10(9)/L)

Comparator

Pre-cancer platelet count below the 40th percentile (<235×10(9)/L)

Outcome

Incident symptomatic venous thromboembolism eventshard clinical

Main Result

Hazard Ratio: 1.98 (95% CI 1.21–3.23)

Absolute Event Rate: 20.5% vs 10.9%

Elevated pre-cancer platelet count is a significant risk factor for future symptomatic venous thromboembolism in patients who subsequently develop cancer, suggesting a role for platelet-leukocyte interactions in cancer-related VTE.

Limitations

Cancer treatment modality was not available
Limited size of the cancer cohort restricted possibilities to evaluate the impact of cancer sites on the association
Cannot answer how platelet indices during active cancer are related to pre-cancer measurements
Unrecognized confounding cannot be ruled out
Platelet count was based on one single measurement

Cite This Study

Jensvoll et al. (2014) conducted a cohort in Venous thromboembolism in cancer and non-cancer subjects (n=25,160). Pre-cancer platelet count ≥295×10^9/L (>80th percentile) vs. Pre-cancer platelet count <235×10^9/L (<40th percentile) was evaluated on Symptomatic venous thromboembolism (VTE) in cancer patients (HR 1.98, 95% CI 1.21-3.23). In cancer patients, a pre-cancer platelet count above the 80th percentile (≥295×10^9/L) was associated with a 2-fold higher risk of symptomatic venous thromboembolism (HR 1.98) compared to a platelet count below the 40th percentile.

synapsesocial.com/papers/6a93bed82cf12ee0be69826d https://doi.org/10.1371/journal.pone.0092011

View Full Paper

Ask AI

Bookmark

March 18, 2014PLoS ONEOpen Access

Platelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Study

View Full Paper

Ask AI

Bookmark

Key result

Why the study?

Does elevated pre-cancer platelet count increase the risk of symptomatic venous thromboembolism in subjects who subsequently develop cancer?

Population

25,160 initially cancer-free subjects who participated in the Tromsø Study in 1994-1995, of whom 2,082 were…

Comparison

Pre-cancer platelet count above the 80th… vs Pre-cancer platelet count below the 40th…

Design

Cohort

Follow-up

up to December 31st, 2009

Authors

HJHilde Jensvoll KBKristine Blix SBSigrid K. Brækkan

Discussion

Member takes

Overview

May flag higher VTE risk in cancer; extends observational links but leaves open validation and trials.

Study Design

Type

Cohort (n=25,160)

Multicenter

Structured PICO

Does elevated pre-cancer platelet count increase the risk of symptomatic venous thromboembolism in subjects who subsequently develop cancer?

Population

Exposure

Pre-cancer platelet count above the 80th percentile (≥295×10(9)/L)

Comparator

Pre-cancer platelet count below the 40th percentile (<235×10(9)/L)

Outcome

Incident symptomatic venous thromboembolism eventshard clinical

Main Result

Hazard Ratio: 1.98 (95% CI 1.21–3.23)

Absolute Event Rate: 20.5% vs 10.9%

Limitations

Cancer treatment modality was not available
Limited size of the cancer cohort restricted possibilities to evaluate the impact of cancer sites on the association
Cannot answer how platelet indices during active cancer are related to pre-cancer measurements
Unrecognized confounding cannot be ruled out
Platelet count was based on one single measurement

Cite This Study

synapsesocial.com/papers/6a93bed82cf12ee0be69826d https://doi.org/10.1371/journal.pone.0092011

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark